Abstract

 The transcatheter edge-to-edge valve repair (TEER) device (TriClip) might be more effective in reducing tricuspid regurgitation severity and improving quality of life compared to medical therapy alone.
 The TEER device (TriClip) may have little impact on all-cause mortality, hospitalization due to heart failure, and 6-minute walk tests compared to medical therapy alone.
 The TEER device (TriClip) demonstrated a numerically higher rate of adverse events than a medical therapy control group in a clinical trial.
 Patients treated with the TEER device (TriClip) had fewer major adverse events (ranging from 2.5% to 7.1%) than the 10% performance goal in the included clinical trial; common major adverse events included major bleeding, single leaflet device attachment, and nonelective cardiovascular surgery. No device embolization or thrombosis were reported.
 We did not identify any studies that met our inclusion criteria to evaluate the effectiveness of the TEER device (TriClip) compared to open heart surgery.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
